Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) dropped 2.1% on Thursday . The stock traded as low as $0.82 and last traded at $0.84. Approximately 403,606 shares traded hands during mid-day trading, an increase of 23% from the average daily volume of 328,857 shares. The stock had previously closed at $0.85.
Analysts Set New Price Targets
Several research firms recently issued reports on ONCY. Leede Financial lowered Oncolytics Biotech from a "strong-buy" rating to a "moderate buy" rating in a report on Wednesday, November 13th. HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Oncolytics Biotech in a research note on Thursday, November 14th. Finally, Raymond James raised shares of Oncolytics Biotech to a "moderate buy" rating in a research report on Thursday, November 14th.
Get Our Latest Stock Report on ONCY
Oncolytics Biotech Stock Performance
The business has a fifty day moving average of $1.08 and a two-hundred day moving average of $1.02. The firm has a market capitalization of $62.71 million, a price-to-earnings ratio of -3.01 and a beta of 1.63.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Recommended Stories
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
